Please check your internet connection and try again.
# Linagliptin
## Overview
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone concentrations, stimulating glucose-dependent insulin release and decreasing glucagon levels. It is unique among DPP-4 inhibitors as it is primarily excreted via the biliary/gastrointestinal route rather than the kidneys.
## Primary Indications
Type 2 diabetes mellitus (as an adjunct to diet and exercise to improve glycemic control).
## Adult Dosing
* **Standard dose:** 5 mg orally once daily.
* **Maximum dose:** 5 mg daily.
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (under 18 years of age).
## Dose Adjustments
* **Renal impairment:** No dose adjustment required.
* **Hepatic impairment:** No dose adjustment required.
* **Geriatric:** No dose adjustment required based on age.
## Contraindications
* History of hypersensitivity reaction to linagliptin (e.g., anaphylaxis, angioedema, exfoliative skin conditions).
* Type 1 diabetes or diabetic ketoacidosis (not effective).
## Adverse Effects
* **Common:** Nasopharyngitis, hypoglycemia (when used with secretagogues or insulin).
* **Serious:** Acute pancreatitis (rare), severe and disabling arthralgia, bullous pemphigoid, hypersensitivity reactions.
## Key Drug Interactions
* **CYP3A4/P-gp Inducers (e.g., Rifampin):** May decrease linagliptin concentrations. If a potent inducer must be used, consider an alternative to linagliptin or monitor glycemic control closely.
* **Insulin/Sulfonylureas:** Increased risk of hypoglycemia; a dose reduction of the insulin or insulin secretagogue may be necessary.
## Monitoring
* **HbA1c:** Checked at least twice yearly in patients meeting goals, or quarterly if not at goal.
* **Pancreatitis:** Monitor for persistent, severe abdominal pain.
* **Skin:** Monitor for blistering or erosions suggestive of bullous pemphigoid.
## Clinical Pearls
* **Unique excretion:** Linagliptin is the only oral DPP-4 inhibitor that does not require renal dose adjustment, making it preferred for patients with chronic kidney disease.
* **Weight neutrality:** Linagliptin is generally weight-neutral.
* **Administration:** May be taken with or without food.
* **Missed dose:** If a dose is missed, take it as soon as remembered, but do not take two doses on the same day.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug information can change frequently. Always consult the most current manufacturer prescribing information, local clinical protocols, and pharmacy databases (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
